Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. (Q54076009)

24 May 2018

title

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. (English)

1 reference

24 May 2018

author name string

Nagaya N

1 reference

24 May 2018

Uematsu M

1 reference

24 May 2018

Okano Y

1 reference

24 May 2018

Satoh T

1 reference

24 May 2018

Kyotani S

1 reference

24 May 2018

Sakamaki F

1 reference

24 May 2018

Nakanishi N

1 reference

24 May 2018

Miyatake K

1 reference

24 May 2018

Kunieda T

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 October 1999

1 reference

24 May 2018

Journal of the American College of Cardiology

published in

1 reference

24 May 2018

volume

1 reference

24 May 2018

issue

1 reference

24 May 2018

page(s)

1188-1192

1 reference

24 May 2018

Primary pulmonary hypertension. A national prospective study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Oral hydralazine therapy for primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Single-lung transplantation for pulmonary hypertension. Three-month hemodynamic follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Primary Pulmonary Hypertension: Improved Long-Term Effects and Survival With Continuous Intravenous Epoprostenol Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Orally active prostacyclin analogue in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Reliability of the determination of cardiac output in man by means of the Fick principle

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Survival in primary pulmonary hypertension. Validation of a prognostic equation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

Additive Effect of Beraprost on Pulmonary Vasodilation by Inhaled Nitric Oxide in Children With Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900312-5

7 January 2021

10.1016/S0735-1097(99)00312-5

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018